Pharmaceuticals

Morning after Pill under Review in Europe

Morning after Pill under Review in Europe

European Medicines Agency has initiated a detailed review of impact of morning after pill as reports suggested lower success rate of the emergency contraceptive in overweight women came.

Solanezumab and bapineuzumab fail in Trials for Alzheimer’s disease

Solanezumab and bapineuzumab fail in Trials for Alzheimer’s disease

Eli Lilly’s solanezumab and J&J’s bapineuzumab have failed in phase III trials on patients suffering from mild to moderate dementia. The trials have not found noticeable improvement in cognitive abilities of the study subjects.

Bapineuzumab trial was carried out of 2200 patients while 2000 patients participated in solanezumab trial. Eli Lilly announced that the company will carry out another trial of solanezumab but bapineuzumab trials have been halted.

Laboratories: 

Amarin’s Shares Fall 26% on Rejection of Vascepa by FDA

Amarin’s Shares Fall 26% on Rejection of Vascepa by FDA

New Jersey based Amarin Corp Plc.'s shares witnessed a fall of 26% after the company announced rejection from the U.S. Food and drug Administration (FDA) for its blood fat-lowering drug, Vascepa.

Location: 
Laboratories: 
Company: 

Schizophrenia Drug Bitopertin Fails in Late-stage Trials: Roche Holding AG

Schizophrenia Drug Bitopertin Fails in Late-stage Trials: Roche Holding AG

Swiss pharmaceutical major Roche informed Tuesday that experimental schizophrenia drug bitopertin failed in two late-stage trials. The results found from the drug use could not reduce negative symptoms among patients. The company will continue with third late-stage study.

Bitopertin was used with along with antipsychotics to reduce symptoms of schizophrenia. Bitopertin could have been the first drug in new class of treatment for the ailment. As per official communication from Roche, the phase III trials could not offer significant improvement after 24 week treatment.

Location: 
Company: 

Novartis Employees Possibly Breached Trial Protocol in Japan

Novartis Employees Possibly Breached Trial Protocol in Japan

Novartis Pharma K.K. (NPKK) acknowledged that employees of its Japanese subsidiary might have improperly handled data for a study of the cancer therapy, Tasigna. The Swiss drug maker claims that the employees had transferred data from research institutes to the University of Tokyo Hospitals for analysis, which is against the rules of the clinical trial.

In actual, the data was supposed to be transferred by research institutes directly to the hospital without being passed on by Novartis employees.

Location: 
Laboratories: 
Company: 

Adcock Ingram Management Plans Expansion outside South Africa

Adcock Ingram Management Plans Expansion outside South Africa

Adcock Ingram management has planned to increase the company operations outside South Africa. The pharmaceutical major has been limited to the South African market. Adcock aims to double its sales with focus on Nigeria, Kenya and other African markets.

Company: 

Drug to Treat Liver Disease found Effective in Trail

Drug to Treat Liver Disease found Effective in Trail

Intercept Pharmaceuticals Inc. has successfully tested a drug that is effective against liver diseases. The trails conducted on patients have shown positive results and could lead to first validated treatment for some of the incurable liver ailments.

In the trial, obeticholic acid of the drug was tested in patients with non-alcoholic steatohepatitis (NASH). NASH is a type of liver inflammation. Fat buildup in liver has been termed as major reason for many of the liver ailments.

Adcock Delays Vote on CFR Pharmaceuticals Offer

Adcock Delays Vote on CFR Pharmaceuticals Offer

Pharmaceutical major Adcock Ingram has delayed shareholder voting on takeover of the company by CFR Pharmaceuticals. The shareholders had decided to take more time to decide about the future of the South African drugmaker. The decision has now been pushed forward to mid-February.

Location: 
Company: 

Novartis Sued in New York over Kick backs to Pharmacy

Novartis Sued in New York over Kick backs to Pharmacy

The New York Attorney General, Eric T. Scheniderman,told that the U.S. state has filed a suit against Novartis over charges that the Swiss drug maker granted bribes to a New York pharmacy company. The bribe was given in order to promote its Exjade drug to treat higher proportion of iron in the blood.

Location: 
Company: 

FDA Approves GSK Application to market Melanoma Drug Combination

FDA Approves GSK Application to market Melanoma Drug Combination

GlaxoSmithKline (GSK) has won approval from the US Food and Drug Administration (FDA) to market melanoma drug combination in US market. The drug maker has received green signal to make melanoma drug by combining two drugs Tafinlar and Mekinist or trametinib.

Laboratories: 
Company: 

Pages

Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More

Tesla announces risky new approach to customer service

During the past few years, Tesla was slammed by a... Read More